Stifel reiterates Buy on Palvella stock, $250 target on new program
Stifel has reaffirmed its Buy rating and $250 price target for Palvella Therapeutics (PVLA) shares, following the company's announcement of a new program utilizing its QTORIN platform. The stock is currently trading at $145.98 with a market capitalization of $2.12 billion. Analysts still rate Palvella as a Strong Buy, with price targets ranging from $207 to $267.
The company is developing a topical formulation of docetaxel for extramammary Paget's disease, a rare cancer with no FDA-approved treatments. Docetaxel has shown activity in metastatic extramammary Paget's disease, but over 25% of patients discontinue treatment due to toxicities. Palvella is conducting IND studies for FDA discussions in the first half of 2027 for a 505(b)(2) regulatory pathway.
The company estimates an over $500 million market opportunity based on a 10,000 U.S. prevalence, $200,000 per year pricing, and 50% diagnosis rate. Despite strong recent performance and momentum, InvestingPro analysis suggests the stock is overvalued relative to its Fair Value. Investors can review additional tips and financial metrics for further evaluation of Palvella's potential.
Palvella recently reported its Q3 2026 earnings, reporting a smaller-than-expected loss of -$1.70 per share, beating estimates of -$1.80. Revenue was reported at $0, aligning with expectations. Concerns about rising expenditures as the company prepares for its first product launch persist. The stock saw a premarket trading decline, but specific price movements are not discussed here. No analyst upgrades or downgrades have been reported recently.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.